Literature DB >> 11988641

Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth.

John J Lehman1, Daniel P Kelly.   

Abstract

Studies in a variety of mammalian species, including humans, have demonstrated a reduction in fatty acid oxidation (FAO) and increased glucose utilization in pathologic cardiac hypertrophy, consistent with reinduction of the fetal energy metabolic program. This review describes results of recent molecular studies aimed at delineating the gene regulatory events which facilitate myocardial energy substrate switches during hypertrophic growth of the heart. Studies aimed at the characterization of transcriptional control mechanisms governing FAO enzyme gene expression in the cardiac myocyte have defined a central role for the fatty acid-activated nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR(alpha)). Cardiac FAO enzyme gene expression was shown to be coordinately downregulated in murine models of ventricular pressure overload, consistent with the energy substrate switch away from fatty acid utilization in the hypertrophied heart. Nuclear protein levels of PPAR(alpha) decline in the ventricle in response to pressure overload, while several Sp and nuclear receptor transcription factors are induced to fetal levels, consistent with their binding to DNA as transcriptional repressors of rate-limiting FAO enzyme genes with hypertrophy. Knowledge of key components of this transcriptional regulatory pathway will allow for the development of genetic engineering strategies in mice that will modulate fatty acid oxidative flux and assist in defining whether energy metabolic derangements play a primary role in the development of pathologic cardiac hypertrophy and eventual progression to heart failure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11988641     DOI: 10.1023/a:1015332726303

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  42 in total

Review 1.  Switches in cardiac muscle gene expression as a result of pressure and volume overload.

Authors:  K Schwartz; K R Boheler; D de la Bastie; A M Lompre; J J Mercadier
Journal:  Am J Physiol       Date:  1992-03

Review 2.  The heart in hypertension.

Authors:  E D Frohlich; C Apstein; A V Chobanian; R B Devereux; H P Dustan; V Dzau; F Fauad-Tarazi; M J Horan; M Marcus; B Massie
Journal:  N Engl J Med       Date:  1992-10-01       Impact factor: 91.245

Review 3.  Energy metabolism of the heart: from basic concepts to clinical applications.

Authors:  H Taegtmeyer
Journal:  Curr Probl Cardiol       Date:  1994-02       Impact factor: 5.200

4.  Activation of PPARgamma coactivator-1 through transcription factor docking.

Authors:  P Puigserver; G Adelmant; Z Wu; M Fan; J Xu; B O'Malley; B M Spiegelman
Journal:  Science       Date:  1999-11-12       Impact factor: 47.728

5.  The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes.

Authors:  R B Vega; J M Huss; D P Kelly
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

6.  The role of the peroxisome proliferator-activated receptor alpha (PPAR alpha) in the control of cardiac lipid metabolism.

Authors:  F Djouadi; J M Brandt; C J Weinheimer; T C Leone; F J Gonzalez; D P Kelly
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  1999 May-Jun       Impact factor: 4.006

Review 7.  Mitochondrial diseases in man and mouse.

Authors:  D C Wallace
Journal:  Science       Date:  1999-03-05       Impact factor: 47.728

8.  Alterations in gene expression in the rat heart after chronic pathological and physiological loads.

Authors:  P M Buttrick; M Kaplan; L A Leinwand; J Scheuer
Journal:  J Mol Cell Cardiol       Date:  1994-01       Impact factor: 5.000

9.  Cardiac hypertrophy in the dog and rat induced by oxfenicine, an agent which modifies muscle metabolism.

Authors:  P Greaves; J Martin; M C Michel; P Mompon
Journal:  Arch Toxicol Suppl       Date:  1984

10.  Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding.

Authors:  A M Feldman; E O Weinberg; P E Ray; B H Lorell
Journal:  Circ Res       Date:  1993-07       Impact factor: 17.367

View more
  49 in total

Review 1.  Heart mitochondria signaling pathways: appraisal of an emerging field.

Authors:  José Marín-García; Michael J Goldenthal
Journal:  J Mol Med (Berl)       Date:  2004-06-23       Impact factor: 4.599

2.  Akt2 deficiency promotes cardiac induction of Rab4a and myocardial β-adrenergic hypersensitivity.

Authors:  Sharon Etzion; Yoram Etzion; Brian DeBosch; Peter A Crawford; Anthony J Muslin
Journal:  J Mol Cell Cardiol       Date:  2010-08-20       Impact factor: 5.000

3.  Cyclophilin D controls mitochondrial pore-dependent Ca(2+) exchange, metabolic flexibility, and propensity for heart failure in mice.

Authors:  John W Elrod; Renee Wong; Shikha Mishra; Ronald J Vagnozzi; Bhuvana Sakthievel; Sanjeewa A Goonasekera; Jason Karch; Scott Gabel; John Farber; Thomas Force; Joan Heller Brown; Elizabeth Murphy; Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

4.  Gene expression-based screening identifies microtubule inhibitors as inducers of PGC-1alpha and oxidative phosphorylation.

Authors:  Zoltan Arany; Bridget K Wagner; Yanhong Ma; Jessica Chinsomboon; Dina Laznik; Bruce M Spiegelman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-17       Impact factor: 11.205

5.  Cardiac transcriptome and dilated cardiomyopathy genes in zebrafish.

Authors:  Yu-Huan Shih; Yuji Zhang; Yonghe Ding; Christian A Ross; Hu Li; Timothy M Olson; Xiaolei Xu
Journal:  Circ Cardiovasc Genet       Date:  2015-01-11

Review 6.  Mitochondria and cardiovascular diseases-from pathophysiology to treatment.

Authors:  Gerasimos Siasos; Vasiliki Tsigkou; Marinos Kosmopoulos; Dimosthenis Theodosiadis; Spyridon Simantiris; Nikoletta Maria Tagkou; Athina Tsimpiktsioglou; Panagiota K Stampouloglou; Evangelos Oikonomou; Konstantinos Mourouzis; Anastasios Philippou; Manolis Vavuranakis; Christodoulos Stefanadis; Dimitris Tousoulis; Athanasios G Papavassiliou
Journal:  Ann Transl Med       Date:  2018-06

7.  Diuretics prevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizing effects in mice.

Authors:  Cherng-Shyang Chang; Pei-Jane Tsai; Junne-Ming Sung; Ju-Yi Chen; Li-Chun Ho; Kumar Pandya; Nobuyo Maeda; Yau-Sheng Tsai
Journal:  Am J Pathol       Date:  2013-11-26       Impact factor: 4.307

Review 8.  Transcriptional regulation of energy substrate metabolism in normal and hypertrophied heart.

Authors:  Rong Tian
Journal:  Curr Hypertens Rep       Date:  2003-12       Impact factor: 5.369

Review 9.  Mitochondria as a drug target in ischemic heart disease and cardiomyopathy.

Authors:  Andrew M Walters; George A Porter; Paul S Brookes
Journal:  Circ Res       Date:  2012-10-12       Impact factor: 17.367

10.  Substrate-enzyme competition attenuates upregulated anaplerotic flux through malic enzyme in hypertrophied rat heart and restores triacylglyceride content: attenuating upregulated anaplerosis in hypertrophy.

Authors:  Kayla M Pound; Natalia Sorokina; Kalpana Ballal; Deborah A Berkich; Mathew Fasano; Kathryn F Lanoue; Heinrich Taegtmeyer; J Michael O'Donnell; E Douglas Lewandowski
Journal:  Circ Res       Date:  2009-02-12       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.